Lacosamide Anfarm

Lacosamide, the active ingredient in Lacosamide Anfarm, is an anti‑epileptic presented as an injectable solution for intravenous use. It is employed to treat partial‑onset seizures in patients with epilepsy, providing an additional therapeutic option when seizures are not adequately controlled by other medications.

GNH USA supplies Lacosamide Anfarm as a licensed, GDP‑compliant international pharmaceutical product, serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements, ensuring consistent product integrity across global markets.

Lacosamide is an anti‑epileptic drug used to manage seizure disorders, particularly those arising from focal brain activity.

Partial‑onset seizures: reduces seizure frequency and severity in patients with focal epilepsy. Epilepsy (adjunctive therapy): provides additional seizure control when other agents are insufficient. Focal epilepsy: serves as a supplementary option for patients with refractory focal seizures.

Lacosamide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Dizziness - Headache - Somnolence - Blurred vision - Fatigue

Serious or Rare Side Effects: - Cardiac arrhythmias or conduction abnormalities - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Suicidal ideation or behavior - Respiratory depression - Anaphylactic reactions - Significant hypotension

When prescribing Lacosamide, clinicians should consider several safety aspects. - Renal impairment: monitor renal function and adjust dosing if necessary. - Hepatic impairment: use with caution and assess liver enzymes regularly. - Cardiac conduction disorders: evaluate ECG and monitor for PR or QRS prolongation. - Concomitant sodium‑channel blockers: increased risk of additive CNS effects. - Pregnancy: risk category unknown; weigh potential benefits against unknown fetal risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Other sodium‑channel blockers (e.g., carbamazepine, phenytoin): may cause additive CNS depression. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can reduce lacosamide plasma levels. - Monoamine oxidase inhibitors: increased risk of cardiac conduction effects.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole, omeprazole): may raise lacosamide concentrations. - Anticoagulants (e.g., warfarin): monitor INR for potential alterations. - Alcohol: may enhance central nervous system depression and dizziness.